Delaware’s top court ruled in GSK’s favor in saying it will review the admissibility of expert evidence in an upcoming trial ...

GSK has won its latest trial over whether its former best-selling ... known as NDMA that had been found in GSK’s heartburn ...

UK-based GlaxoSmithKline PLC (GB:GSK) has won the latest U.S. trial concerning its heartburn drug Zantac (ranitidine), amid ...

The latest trial over claims that the discontinued heartburn drug Zantac causes cancer ended with a hung jury on Wednesday, ...

Twelve days after GSK secured a key win in Florida ... to take to early trials. On the first track, plaintiffs have retained 10 experts to offer their opinions on whether ranitidine can cause ...

GSK plc (LSE/NYSE: GSK), a leading global pharmaceutical company, has reached a confidential settlement in a Zantac (ranitidine ... SWIFT-2 phase III clinical trials. However, the company ...

Plaintiffs in the case have argued that ranitidine can cause cancer. The drug was marketed for years by GSK (GSK) under the brand name Zantac and by various generic drugmakers. GSK (GSK ...

Delaware’s top court is set to hear an appeal from GSK and other pharmaceutical ... In December 2022, approximately 50,000 Zantac cases were dismissed during a pre-trial hearing in Florida.

(Reuters) - GSK won the latest trial over claims that discontinued heartburn drug Zantac caused cancer, as a jury on Monday found that the drug was not responsible for an Illinois woman's illness ...

Zamboni is expected to say the 'Tanner study - which was not submitted to the FDA until 2019 - provides evidence that GSK knew about Zantac's potential health impacts, but failed to make the ...

GSK plc (LSE/NYSE: LON:GSK), a leading global pharmaceutical company, has reached a confidential settlement in a Zantac (ranitidine ... in its SWIFT-1 and SWIFT-2 phase III clinical trials. However, ...